Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Guardant Health, Inc. - Common Stock
(NQ:
GH
)
107.42
+0.31 (+0.29%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
20
21
Next >
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
June 03, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Named to TIME100 Most Influential Companies
May 31, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
May 30, 2024
From
Guardant Health, Inc.
Via
Business Wire
Evaluating Guardant Health: Insights From 5 Financial Analysts
↗
May 24, 2024
Via
Benzinga
Key Takeaways From Guardant Health Analyst Ratings
↗
April 24, 2024
Via
Benzinga
Analyst Expectations For Guardant Health's Future
↗
April 05, 2024
Via
Benzinga
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
↗
May 29, 2024
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir
Via
Benzinga
Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns
↗
May 27, 2024
We're heading into our third year of this raging bull market, and there doesn't appear to be any end in sight for these high-return stocks.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 27, 2024
Via
Benzinga
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
↗
May 24, 2024
Via
Benzinga
FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
↗
May 24, 2024
FDA panel recommends approval for Guardant Health's Shield blood test for colorectal cancer screening.
Via
Benzinga
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
↗
May 24, 2024
The companies are likely to soon battle it out in the colon cancer screening market.
Via
Investor's Business Daily
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
May 23, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 23, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
May 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
↗
May 21, 2024
FDA staff reviewers raise concerns over Guardant Health's experimental Shield blood test for colorectal cancer, citing low sensitivity in detecting certain tumor types. Shield aims to improve early CRC...
Via
Benzinga
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 21, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16, 2024
From
Guardant Health, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 10, 2024
Via
Benzinga
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q1 2024
↗
May 09, 2024
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
May 09, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
May 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
May 07, 2024
From
Guardant Health, Inc.
Via
Business Wire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
↗
April 22, 2024
Via
Benzinga
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
April 22, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
April 18, 2024
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
April 03, 2024
From
Guardant Health, Inc.
Via
Business Wire
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
↗
April 02, 2024
The companies are working to detect colon cancer and precancerous markers in blood and/or stool.
Via
Investor's Business Daily
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.